Abstract: A phage dispensing system comprises a user interface, a phage treatment computing system, a phage laboratory, and a phage dispensing apparatus, including a dispensing kiosk. The user interface allows a treating physician to request testing of a patient sample by the phage laboratory to identify a phage mixture treatment. The phage computing system arranges shipping of the sample and provision of the identified phage mixture treatment to a dispensing apparatus located near the patient. The dispensing apparatus has a stock of phage vials which are used to prepare and dispense doses of the identified phage mixture treatment.

Abstract: A method of selecting a phage formulation is described wherein the method comprises storing bacterial infection/contamination data at one or more treatment locations in a spatio-temporal infection database, the database comprising at least one of the following data fields: (1) a clinical indication, (2) a bacteria identification, (3) a clinical outcome, (4) a phage resistance status, (5) a phage susceptibility profile, (6) an antibiotic susceptibility profile, and/or (7) a lab test result relating to any one of (1)-(6); identifying one or more phage suitable for inclusion in the phage formulation by analyzing the data fields of (1)-(7) in the database to identify to one or more infections associated with a treatment location during a historical time period based at least on one or more of a frequency of infections/contamination, a geographic clustering of infections/contamination, and/or phage usage data; and generating a selected list of phage to be included in the phage formulation.

Abstract: A computer implemented method of generating a machine learning model for interpreting host phage response data comprising receiving datasets and labels for a host phage response, training a machine learning model and using this model to estimate the efficacy of a test phage in inhibiting growth of a test bacteria.

Abstract: A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be “universal”; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1×109 PFU/ml) for use in therapeutic applications.

Abstract: A transdermal membrane comprising a non-infectious icosahedral phage vaccine displaying an antigen is described wherein the membrane is stable at room temperature for greater than 3 months and uses thereof to vaccinate a subject against the antigen.

Abstract: The invention relates to the production of biopharmaceuticals and, more particularly, to a novel method of monitoring for contamination of such products with components of any host cells used or involved in the manufacturing process. The method comprises a step of determining the presence in a biopharmaceutical (e.g. a therapeutic phage composition) of a ribosomal subunit protein unique to bacteria (or protein fragments thereof) or a nucleic acid molecule comprising a nucleotide sequence derived from a gene encoding a ribosomal subunit protein unique to bacteria.

Abstract: A simple method and kit for preserving clinical specimens and other biological samples, particularly for the purpose of preserving the concentration of bacteriophage and/or bacteria present in a sample, is described. The method involves rapidly lowering the temperature of the sample (e.g. freezing) to a temperature of ?50° C. or lower (especially about ?78° C.) in the presence of a suitable cryoprotectant (e.g. 20% glycerol). In one application, the method is used with clinical samples (e.g. urine) taken from a patient undergoing phage therapy for a bacterial infection, wherein the method permits the samples to be transported and/or stored following collection such that the viability of any phage and/or bacteria present is maintained while also inhibiting potential interactions between the phage and bacteria. After thawing of the samples, the samples may be analyzed for phage and/or bacterial concentration to provide information on the effectiveness of the phage therapy.

Abstract: Methods and systems for pattern search and analysis to identify and select therapeutic molecules that can be used to treat bacterial infections or contaminations. Examples include methods and systems for pattern search and analysis to identify and select bacteriophage based on comparison of the genomes of a query bacterium and/or a query phage strain to a therapeutic molecule-host training set of bacterial strains and/or phage strains in which the phage strains (or other therapeutic molecules) have been shown to have the capacity to act as an antibacterial agent by either killing, replicating in, lysing and/or inhibiting the growth of the bacterial strains in the training set. Therapeutic compositions, including phage, identified using the methods described herein can then be used to treat bacterial infections in a subject and/or contamination in the environment.

Abstract: A phage dispensing system comprises a user interface, a phage treatment computing system, a phage laboratory, and a phage dispensing apparatus, including a dispensing kiosk. The user interface allows a treating physician to request testing of a patient sample by the phage laboratory to identify a phage mixture treatment. The phage computing system arranges shipping of the sample and provision of the identified phage mixture treatment to a dispensing apparatus located near the patient. The dispensing apparatus has a stock of phage vials which are used to prepare and dispense doses of the identified phage mixture treatment.